免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据，仅供一般参考，不构成医疗建议、诊断、治疗建议或投资建议。

FDA 510(k)

ARK 左乙拉西坦II测定法

K号: K232522 · 2024-02-27

申请人Ark Diagnostics, Inc.
决定日期2024-02-27
产品代码ORI
咨询委员会TX 请注意，由于您没有提供具体的医疗设备监管文本，我无法进行翻译。请提供具体的文本内容，以便我能够按照您的要求进行翻译。
决定实质等同

器械摘要

ARK Levetiracetam II Assay is the device name listed in this FDA 510(k) record. The listed applicant is Ark Diagnostics, Inc.. It received FDA 510(k) clearance on 2024-02-27 under 510(k) number K232522. The device is classified under product code ORI. It was reviewed by the TX advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the ARK Levetiracetam II Assay?

ARK Levetiracetam II Assay is a medical device that received FDA 510(k) clearance on 2024-02-27. The listed applicant is Ark Diagnostics, Inc.. The 510(k) number is K232522.

When did ARK Levetiracetam II Assay receive FDA 510(k) clearance?

ARK Levetiracetam II Assay received FDA 510(k) clearance on 2024-02-27, under 510(k) number K232522.

Who is the listed applicant for ARK Levetiracetam II Assay?

The FDA 510(k) record lists Ark Diagnostics, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for ARK Levetiracetam II Assay?

The FDA product code for ARK Levetiracetam II Assay is ORI.

相关临床试验

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。

NCT07608549FLASHPilot 1期安全性研究NOT_YET_RECRUITINGNCT06562205PAP系统外部临床研究（ECS）NOT_YET_RECRUITINGNCT06443177交感神经调节对动脉瘤性蛛网膜下腔出血继发脑动脉痉挛的影响SUSPENDEDNCT07095751人工智能辅助尿路摄像头评估系统，用于诊断膀胱癌NOT_YET_RECRUITING

列明Ark Diagnostics, Inc.为申报人的其他记录

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系；请查阅链接的官方来源。

K232017ARK 甲氨蝶呤II测定法K231752ARK 氢可酮测定法K201089ARK 拉考沙胺测定法K200197ARK 芬太尼II测定法K182280ARK 曲马多检测K182779ARK EDDP 测定法

查看所有 10 个设备 →

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息，请务必参考官方记录。

↑